Further complicating treatment approaches is the growing appreciation that neuroblastoma metabolism does not entirely conform to the classical glycolytic “Warburg effect,” and that high-risk tumours, in particular MYCN-amplified, have considerable metabolic flexibility and a capacity to harness mitochondrial OXPHOS for energy extraction. This evidence concerns the gene MYCN and neuroblastoma.